Study wrapper · #1304
From adiposity to multisystem morbidity: the case for weight loss as disease modification.
Editor's note
The useful contribution here is the honest map of where the randomised evidence exists and where it does not: the incretin trial programme has produced hard outcome data for a handful of conditions and left most of the multisystem burden of obesity under-investigated. This is a narrative review rather than a quantitative synthesis, so the causal claims rest on the authors' triangulation judgement, and reviews by senior trialists in this field commonly carry industry advisory relationships worth checking in the declarations. Readers should note the framing distinction the paper draws between weight loss as a marker and weight loss as the mechanism of benefit, which the authors flag as still unresolved and dependent on mediation analyses yet to be done.
Plain-language abstract
This Lancet Diabetes and Endocrinology review triangulates epidemiology, genetic (Mendelian randomisation) evidence, observational weight-change data and randomised trials to ask which obesity-related conditions actually improve when body weight falls. The authors find strong randomised support for disease modification in type 2 diabetes and heart failure with preserved ejection fraction, and much thinner evidence for musculoskeletal, respiratory and mental-health conditions. They credit semaglutide and tirzepatide, at average weight losses of roughly 14 to 20 percent, with generating the first large-scale randomised evidence in this area.